---
title: "IceCure says West Cancer Center begins enrollment for ChoICE breast cancer cryoablation study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296489702.md"
description: "IceCure Medical announced that West Cancer Center has received IRB clearance to begin patient enrollment for the ChoICE post-marketing study of ProSense in low-risk breast cancer. Enrollment is expected in the coming weeks, aiming to expand real-world evidence and support commercial uptake among women aged 70 and older."
datetime: "2026-08-20T12:20:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296489702.md)
  - [en](https://longbridge.com/en/news/296489702.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296489702.md)
generator: "portal-rs"
---

# IceCure says West Cancer Center begins enrollment for ChoICE breast cancer cryoablation study

-   IceCure Medical announced IRB clearance at West Cancer Center to start the ChoICE post-marketing study of ProSense in low-risk breast cancer. \* Patient enrollment is expected in the coming weeks, expanding real-world evidence for a device already cleared for use in women aged 70 and older. \* Earlier ICE3 trial results have already been presented, supporting FDA marketing authorization and showing low recurrence with favorable cosmetic satisfaction. \* The new study aims to reinforce adoption by validating outcomes in routine practice, supporting commercial uptake in an older patient segment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ICCM.US](https://longbridge.com/en/quote/ICCM.US.md)

## Related News & Research

- [IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation](https://longbridge.com/en/news/295804964.md)
- [IceCure adds Adventist Health Glendale as enrolling site for ChoICE breast cancer cryoablation study](https://longbridge.com/en/news/295106064.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [09:10 ETIceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation](https://longbridge.com/en/news/295805121.md)
- [Late-breaking data for Abbott’s TactiFlex™ Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases](https://longbridge.com/en/news/297521993.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**